Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3616

1.

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.

Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0085. doi: 10.1634/theoncologist.2018-0085. [Epub ahead of print]

PMID:
30120166
2.

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.

Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0184. doi: 10.1634/theoncologist.2018-0184. [Epub ahead of print]

PMID:
30120165
3.

Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.

Griguolo G, Pouderoux S, Dieci MV, Jacot W, Bourgier C, Miglietta F, Firmin N, Conte P, Viala M, Guarneri V, Darlix A.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0200. doi: 10.1634/theoncologist.2018-0200. [Epub ahead of print]

PMID:
30120164
4.

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.

Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE, Pazdur R.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0221. doi: 10.1634/theoncologist.2018-0221. [Epub ahead of print]

PMID:
30120163
5.

In Reply.

Dang CT, Singh JC, Steingart RM, Yu AF.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0101. doi: 10.1634/theoncologist.2018-0101. [Epub ahead of print] No abstract available.

PMID:
30120162
6.

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).

García-Alfonso P, Benavides M, Falcó E, Muñoz A, Gómez A, Sastre J, Rivera F, Montagut C, Salgado M, López-Ladrón A, López R, Ruiz de Mena I, Durán G, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0316. doi: 10.1634/theoncologist.2018-0316. [Epub ahead of print]

PMID:
30120161
7.

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.

Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S, Goldberg KB, McKee AE, Kaminskas E, Farrell A, Pazdur R.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0295. doi: 10.1634/theoncologist.2018-0295. [Epub ahead of print]

PMID:
30120160
8.

Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?

Shah AN, Gradishar WJ.

Oncologist. 2018 Aug 17. pii: theoncologist.2017-0672. doi: 10.1634/theoncologist.2017-0672. [Epub ahead of print] Review.

PMID:
30120159
9.

Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.

Sato T, Soejima K, Fujisawa D, Takeuchi M, Arai D, Nakachi I, Naoki K, Kawada I, Yasuda H, Ishioka K, Nukaga S, Kobayashi K, Masaki K, Inoue T, Hikima K, Nakamura M, Ohgino K, Oyamada Y, Funatsu Y, Terashima T, Miyao N, Sayama K, Saito F, Sakamaki F, Betsuyaku T.

Oncologist. 2018 Aug 17. pii: theoncologist.2017-0329. doi: 10.1634/theoncologist.2017-0329. [Epub ahead of print]

PMID:
30120158
10.

Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.

Williams CP, Kenzik KM, Azuero A, Williams GR, Pisu M, Halilova KI, Ingram SA, Yagnik SK, Forero A, Bhatia S, Rocque GB.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0076. doi: 10.1634/theoncologist.2018-0076. [Epub ahead of print]

PMID:
30120157
11.

Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?

Loupakis F, Schirripa M, Intini R, Bergamo F, Bertorelle R, Fassan M, Dadduzio V, Merigliano S, Pilati P, Urso ELD, Cillo U, Rugge M, Lonardi S, Zagonel V.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0180. doi: 10.1634/theoncologist.2018-0180. [Epub ahead of print]

PMID:
30120156
12.

Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.

Kawakami H, Takeno A, Endo S, Makari Y, Kawada J, Taniguchi H, Tamura S, Sugimoto N, Kimura Y, Tamura T, Fujitani K, Sakai D, Shimokawa T, Kurokawa Y, Satoh T.

Oncologist. 2018 Aug 16. pii: theoncologist.2018-0175. doi: 10.1634/theoncologist.2018-0175. [Epub ahead of print]

PMID:
30115736
13.

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.

Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, Shord S, Przepiorka D, Farrell AT, McKee AE, Pazdur R.

Oncologist. 2018 Aug 16. pii: theoncologist.2018-0222. doi: 10.1634/theoncologist.2018-0222. [Epub ahead of print]

PMID:
30115735
14.

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.

Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H, Von Hoff DD.

Oncologist. 2018 Aug 16. pii: theoncologist.2017-0665. doi: 10.1634/theoncologist.2017-0665. [Epub ahead of print]

PMID:
30115734
15.

Amyloid Precursor Protein Is Associated with Aggressive Behavior in Nonluminal Breast Cancers.

Tsang JYS, Lee MA, Ni YB, Chan SK, Cheung SY, Chan WW, Lau KF, Tse GMK.

Oncologist. 2018 Aug 14. pii: theoncologist.2018-0012. doi: 10.1634/theoncologist.2018-0012. [Epub ahead of print]

PMID:
30108157
16.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F.

Oncologist. 2018 Aug 14. pii: theoncologist.2018-0058. doi: 10.1634/theoncologist.2018-0058. [Epub ahead of print]

PMID:
30108156
17.

Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.

AlHarbi M, Ali Mobark N, AlMubarak L, Aljelaify R, AlSaeed M, Almutairi A, Alqubaishi F, Hussain ME, Balbaid AAO, Said Marie A, AlSubaie L, AlShieban S, alTassan N, Ramkissoon SH, Abedalthagafi M.

Oncologist. 2018 Aug 13. pii: theoncologist.2018-0163. doi: 10.1634/theoncologist.2018-0163. [Epub ahead of print]

PMID:
30104292
18.

Interleukin-2 Can Cure Kidney Cancer.

Dutcher JP, Wiernik PH.

Oncologist. 2018 Aug 13. pii: theoncologist.2018-0038. doi: 10.1634/theoncologist.2018-0038. [Epub ahead of print] No abstract available.

PMID:
30104291
19.

Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation.

Tolay S, Nair R, McIntosh AF, Sopka DM, Nair SG.

Oncologist. 2018 Aug 13. pii: theoncologist.2018-0205. doi: 10.1634/theoncologist.2018-0205. [Epub ahead of print]

PMID:
30104290
20.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.

Oncologist. 2018 Aug 13. pii: theoncologist.2017-0530. doi: 10.1634/theoncologist.2017-0530. [Epub ahead of print]

PMID:
30104289

Supplemental Content

Loading ...
Support Center